Microsoft word - document15
The Southwest Oncology Group Invites You to Attend the Spring 2007 Group Meeting
At the Hyatt Regency Hotel in Chicago, Illinois
To register for the meeting, review the schedule, plan your travel, and view details of the Group Meeting please use the link below.
Also don’t miss our Plenary Session on Saturday, May 5, 2007, from 8:30 - 11:00 a.m.
The highlight this year for the plenary session is Innovation for Increased
We all know, for example, the Europeans are currently conducting Phase III
trials more efficiently than Americans. The plenary presentations will focus on recent studies
completed through successful collaborations and/or innovative approaches. SWOG Group Chair
Laurence Baker, DO, will also give a presentation, “Strategic Response to Budget Cuts.” And as
always, there will be a few surprises!
Abstracts illustrating innovative approaches include:
Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and
Etoposide in Patients with Extensive Stage Small Cell Lung Cancer Presenter:
Primo Lara, Jr, MD, UC Davis Cancer Center C9710:
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or
Without Arsenic Trioxide (AS2O3) (NSC #706363) as Initial Consolidation Therapy
Followed by Intermittent Tretinoin Maintenance Therapy Versus Observation for Patients
with Untreated Acute Promyelocytic Leukemia Presenter:
Steven Coutre, MD, Stanford University S0205:
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus
Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with
Advanced Pancreas Cancer Presenter:
Phillip Phillip, MD, PhD, Karmanos Cancer Center S8897:
Pharmacogenetics and Breast Cancer Treatment Outcomes: Results on
Oxidative Stress Related Genotypes (MPO, MnSOD) from a Southwest Oncology Group
Intergroup Trial Presenter:
Christine Ambrosone, PhD, Roswell Park Cancer Institute
Discussants include Fred Appelbaum, MD, Fred Hutchinson Cancer Center; Joe Nevins, PhD,
Duke University; Peter O’Dwyer, MD, University of Pennsylvania; Richard Schilsky, MD, CALBG,
University of Chicago; and other internationally renowned experts.
Our Translational Medicine Meeting, Friday, May 4, 4:30 - 6:00 p.m., will offer Translational
Medicine Strategies for Patient Enrichment.
Speakers include Joe Nevins, PhD, Director of the
IGSP Center for Genome Technology at Duke University; Peter O’Dwyer, MD, Experimental
Therapeutics Director at the University of Pennsylvania Cancer Center; and John Crowley, PhD,
SWOG Group Biostatistician and Director of the SWOG Statistical Center and Data Operations
Office. For more information about the upcoming meeting, please see our Group Meeting News at
We look forward to your participation in the SPRING 2007 SWOG GROUP MEETING!
Some Food for Thought About Effect Size Howard S. Bloom Mark W. Lipsey Vanderbilt University March 11, 2004 The following examples highlight some important facts of life about the metric of effect size. The definition of effect size that is used equals the difference in mean outcomes for two groups (usually a treatment group and a control group) divided by the standard d
GEBRAUCHSINFORMATION: INFORMATION FÜR DEN ANWENDER ENDOXAN „Baxter“ 50 mg – Dragees Wirkstoff: Cyclophosphamidmonohydrat Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Einnahme dieses Arzneimittels beginnen. - Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals lesen. Wenn Sie weitere Fragen haben, wenden Sie s